You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

oral decitabine

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Aurora, Colorado
  • +2 more
Jan 3, 2023

Head Neck Cancer Trial in Boston (Oral Decitabine, Durvalumab)

Active, not recruiting
  • Head and Neck Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 30, 2022

Malignant Melanoma Trial in Aurora (Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab)

Recruiting
  • Malignant Melanoma
  • Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
  • Aurora, Colorado
    University of Colorado Hospital
May 25, 2022

MDS Trial in Hangzhou (IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine)

Recruiting
  • Myelodysplastic Syndromes
  • IV Decitabine
  • +2 more
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,Zhejiang University School of Medi
Oct 23, 2023

Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)

Recruiting
  • Acute Myeloid Leukemia
  • Decitabine and Cedazuridine
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Mesothelioma
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 1, 2023

MDS, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial in Sydney (Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET,

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
  • Defactinib
  • Sydney, New South Wales, Australia
  • +3 more
Jan 12, 2023

Solid Tumor Trial in Los Angeles, Baltimore (Decitabine, Cedazuridine)

Recruiting
  • Solid Tumor
  • Los Angeles, California
  • +1 more
Nov 18, 2021

Acute Myeloid Leukemia Trial in Nashville (Biopsy of Bone, Cytarabine, Daunorubicin)

Recruiting
  • Acute Myeloid Leukemia
  • Biospecimen Collection
  • +5 more
  • Buffalo, New York
  • +1 more
Jan 27, 2023

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine and Cedazuridine
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Healthy Trial in San Antonio (Decitabine, Tetrahydrouridine)

Recruiting
  • Healthy
  • San Antonio, Texas
    Worldwide Clinical Trails Early Phase Services
Apr 14, 2023

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Newcastle (Bisantrene DiHCl

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Bisantrene Dihydrochloride (high dose)
  • +3 more
  • Newcastle, New South Wales, Australia
    Calvary Mater
Jul 14, 2022

MDS, Leukemia, Myelomonocytic, Chronic Trial (decitabine, Spartalizumab, Sabatolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic
  • (no location specified)
Aug 5, 2022

Acute Myeloid Leukemia Trial in Houston (SNDX-5613, Venetoclax, ASTX727)

Recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2022

MDS/MPN Trial in Nashville (ASTX727, Itacitinib)

Recruiting
  • MDS/MPN
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Jun 20, 2022

MDS (MDS) Trial (Pevonedistat, Decitabine, Cedazuridine)

Withdrawn
  • Myelodysplastic Syndromes (MDS)
  • (no location specified)
Sep 23, 2021

Sickle Cell Disease Trial in Chicago (Nicotinamide)

Recruiting
  • Sickle Cell Disease
  • Chicago, Illinois
    University of Illinois at Chicago College of Medicine
Mar 21, 2022

MDS, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia Trial in Boston (Inqovi)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 29, 2021

Myelodysplastic Syndrome (MDS) Trial in United States (MBG453, Azacitidine, Decitabine)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • Chandler, Arizona
  • +22 more
Dec 5, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts Trial (Biospecimen

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • +3 more
  • Biospecimen Collection
  • +3 more
  • (no location specified)
Oct 27, 2022

Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

Recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 18, 2022

Sickle Cell Disease Trial in Adana, Mersin (NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo)

Recruiting
  • Sickle Cell Disease
  • NDec - oral decitabine-tetrahydrouridine
  • +2 more
  • Oakland, California
  • +39 more
Jan 24, 2023

Myelodysplastic Syndrome, MDS Trial in Canada, United States (ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727

Completed
Has Results
  • Myelodysplastic Syndrome
  • MDS
  • ASTX727 Dose Escalation
  • +2 more
  • Phoenix, Arizona
  • +16 more
Dec 1, 2020